ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1388

Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes

Anthony Dolomisiewicz1, Hanifah Ali2, Punyasha Roul3, Yangyuna Yang1, Grant Cannon4, Joshua Baker5, Ted Mikuls6, Kaleb Michaud1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, 3UNMC, Omaha, NE, 4Salt Lake City VA, Salt Lake city, 5University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 6Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Keywords: Comorbidity, Epidemiology, Outcome measures, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The Rheumatic Disease Comorbidity Index (RDCI) was designed to quantify comorbidity burden for risk stratification of health outcomes in patients with rheumatic disease. Developed from self-reported conditions and previously validated using ICD-9 codes, the RDCI has yet to be adapted to the ICD-10 coding system despite regular use for outcomes research in rheumatology. We aimed to develop, and validate the performance of, an ICD-10 code list for the RDCI.

Methods: We defined ICD-9 and ICD-10 era cohorts spanning the transition from ICD-9 to ICD-10 within the Veterans Affairs Rheumatoid Arthritis Registry, a multicenter prospective cohort of U.S. Veterans with RA. Comorbidities were collected from linked, national VA administrative data over a two-year period in both cohorts using existing ICD-9 codes and a new ICD-10 code list generated from diagnosis crosswalks and clinical expertise. Over a subsequent two-year follow-up period, MDHAQ scores were obtained from the registry and mortality was ascertained from linked VA death records. ICD-9 and ICD-10 derived comorbidity frequencies and RDCI scores were compared using Cohen’s Kappa and Intraclass Correlation Coefficients (ICC). The ability of the RDCI to improve the prediction of functional status and mortality was assessed using multivariable regression models and goodness of fit statistics (AIC, QICu).

Results: The ICD-9 (n=1,082) and ICD-10 (n=1,445) cohorts were predominantly male (89%, 87%), Caucasian (77%, 74%), and middle to older-aged (mean 67 years, 68 years). Mean (SD) RDCI scores were 2.95 (1.73) for ICD-9 and 2.93 (1.75) for ICD-10 cohorts (Table 1). Among individuals observed during both ICD-9 and ICD-10 eras (n=862), RDCI scores had moderate agreement (ICC 0.71 [0.68-0.74]). Prevalence of comorbidities were similar between coding systems with absolute differences less than 4% (range: 0.3 to 3.9%). Myocardial infarction, hypertension, diabetes mellitus, depression, stroke, other cardiovascular, lung disease, and cancer had moderate agreement or higher (range κ: 0.47 to 0.84), while fracture and ulcer/stomach problem had slight and fair agreement (κ=0.13; κ=0.27) (Table 1). Higher RDCI scores were associated with a greater risk of death, and model performance improved with the addition of the RDCI score in both ICD-9 and ICD-10 cohorts (Table 2). The reduction in AIC (better model performance) was greater in the ICD-10 cohort than ICD-9 (fully adjusted models -23.02 vs. -1.11). Higher RDCI scores were also associated with worse functional status (Table 3). A greater reduction in QICu (better model performance) was seen in the ICD-10 than the ICD-9 cohort with the addition of the RDCI scores to the models predicting MDHAQ (fully adjusted models -60.79 vs. -21.09).

Conclusion: The newly proposed ICD-10 codes for the RDCI generated comparable RDCI scores and chronic disease prevalence estimates to those derived from previously validated ICD-9 codes. RDCI scores calculated using ICD-10 codes are highly predictive of functional status and mortality, comparing favorably to scores based on ICD-9 codes. The proposed ICD-10 codes for the RDCI can be used in outcomes research spanning the ICD-10 era.

Supporting image 1

Table 1. Agreement of RDCI scores and prevalence of comorbidities

Supporting image 2

Table 2. Performance of RDCI score for predicting mortality

Supporting image 3

Table 3. Performance of the RDCI for predicting Multidimensional Health Assessment Questionnaire Scores


Disclosures: A. Dolomisiewicz, None; H. Ali, None; P. Roul, None; Y. Yang, None; G. Cannon, None; J. Baker, Bristol Myers Squibb, Pfizer, CorEvitas LLC, Burns-White, LLC, RediTrex; T. Mikuls, Gilead Sciences, Bristol-Myers Squibb, Horizon, Sanofi, Pfizer Inc; K. Michaud, None; B. England, Boehringer-Ingelheim.

To cite this abstract in AMA style:

Dolomisiewicz A, Ali H, Roul P, Yang Y, Cannon G, Baker J, Mikuls T, Michaud K, England B. Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/updating-and-validating-the-rheumatic-disease-comorbidity-index-to-incorporate-icd-10-diagnostic-codes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/updating-and-validating-the-rheumatic-disease-comorbidity-index-to-incorporate-icd-10-diagnostic-codes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology